Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Goodwill (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Goodwill for 6 consecutive years, with $44.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill changed 0.0% to $44.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.5 million, a 0.0% change, with the full-year FY2025 number at $44.5 million, changed 0.0% from a year prior.
  • Goodwill was $44.5 million for Q4 2025 at Lexicon Pharmaceuticals, roughly flat from $44.5 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $44.5 million in Q1 2023 to a low of $44.5 million in Q1 2023.
  • A 3-year average of $44.5 million and a median of $44.5 million in 2023 define the central range for Goodwill.
  • Biggest YoY gain for Goodwill was 0.0% in 2024; the steepest drop was 0.0% in 2024.
  • Lexicon Pharmaceuticals' Goodwill stood at $44.5 million in 2023, then changed by 0.0% to $44.5 million in 2024, then changed by 0.0% to $44.5 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Goodwill are $44.5 million (Q4 2025), $44.5 million (Q3 2025), and $44.5 million (Q2 2025).